Satellogic Signs Three-Year Agreement with Government of Albania to Access Dedicated Satellite Constellation
29.9.2022 13:00:00 EEST | Business Wire | Press release
Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data collection, announced today that it has reached a three-year agreement with the Government of Albania to develop a Dedicated Satellite Constellation. This unique program derives from Satellogic’s Constellation-as-a-Service model and will provide Albania with responsive satellite imagery capabilities across its sovereign territory.
Satellogic’s unique offering enables municipal, state, and national governments to manage a fleet of satellites over a specific area of interest and develop an EO imaging program at unmatched frequency, resolution, and cost. Satellogic will enable Albania to address pressing issues involving agriculture management, illegal crops, illegal construction activity, traffic management, wildfire monitoring, border security, and environmental monitoring through high-quality imagery with country-wide capacity at a cost-effective price point.
Albania will have priority access to two satellites, which will be named “Albania-1” and “Albania-2”, that are expected to join Satellogic’s fleet in its upcoming satellite launch with SpaceX.
“With the Dedicated Satellite Constellation, Satellogic will accelerate Albania’s participation in the New Space Economy. Additionally, these satellites will provide unprecedented, country-wide situational awareness via the best data from space,” said Emiliano Kargieman, CEO and Co-Founder of Satellogic. “Albania is aiming to develop its involvement in the space community by leveraging the power of high-resolution satellite imagery, and we’re excited for the opportunity to support the country’s ambitions as well as its duties as a member of NATO.”
Through Satellogic’s cloud infrastructure, Albania will have access to responsive tasking, analysis, and dissemination of critical insights and information. Satellogic will facilitate training of remote-sensing specialists within the Albanian Government to assist in the analysis and dissemination of satellite-derived products to various ministries in the country and build the capacity of the Albanian space economy.
Today’s news follows Satellogic’s recent announcem ent of a contract to monitor all subnational protected areas on the planet through the new GREEN+ Jurisdictional Programme. As part of this agreement, Satellogic will collect high-resolution satellite imagery over all the Earth’s forests until 2025, allowing individuals and organizations to accurately monitor the compliance of signatory jurisdictions to avoid deforestation.
About Satellogic
Founded in 2010 by Emiliano Kargieman and Gerardo Richarte, Satellogic (NASDAQ:SATL) is the first vertically integrated geospatial company, driving real outcomes with planetary-scale insights. Satellogic is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers.
Satellogic’s mission is to democratize access to geospatial data of high-resolution images and analytics through its information platform to help solve the world’s most pressing problems including climate change, energy supply, and food security. Using its patented Earth imaging technology, Satellogic unlocks the power of EO to deliver high-quality, planetary insights at the lowest cost in the industry.
With more than a decade of experience in space, Satellogic has proven technology and a strong track record of delivering satellites to orbit and high-resolution data to customers at the right price point.
To learn more, please visit: https://satellogic.com/investors/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning future developments and their potential effects on Satellogic and include statements concerning Satellogic’s strategies, Satellogic’s future opportunities, and the commercial and governmental applications for Satellogic’s technology. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by, an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Satellogic. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) Satellogic’s ability to scale its constellation and to do so on Satellogic’s projected timeframe, (ii) Satellogic’s ability to continue to meet image quality expectations, to continue to enhance the capability of its network of satellites and to continue to offer superior unit economics, (iii) Satellogic’s ability to become or remain an industry leader, (iv) the number of commercial applications for Satellogic’s products and services, (v) Satellogic’s ability to address all commercial applications for satellite imagery, changes in the competitive and highly regulated industries in which Satellogic operates, variations in operating performance across competitors and changes in laws and regulations affecting Satellogic’s business, (vi) the ability to implement business plans, forecasts and other expectations, and to identify and realize additional opportunities, (vii) the risk of downturns in the commercial launch services, satellite and spacecraft industry, (viii) the risk that Satellogic and its current and future collaborators are unable to successfully develop and commercialize Satellogic’s products or services, or experience significant delays in doing so, (ix) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (x) the risk of product liability or regulatory lawsuits or proceedings relating to Satellogic’s products and services, and (xi) the risk that Satellogic is unable to secure or protect its intellectual property. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 20-F and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Satellogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Satellogic can give no assurance that it will achieve its expectations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928006119/en/
Contact information
Investor Relations:
MZ Group
Chris Tyson/Larry Holub
(949) 491-8235
SATL@mzgroup.us
Media Relations:
Satellogic
pr@satellogic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
